SAN CLEMENTE, Calif.--(BUSINESS WIRE)--VertiFlex®, Inc., a leading innovator of minimally invasive and motion preserving spinal surgery technologies, today announced the completion of enrollment in its pivotal IDE clinical trial of the Superion® Interspinous Spacer (ISS). The results of the Superion trial will form the basis for a PMA approval application to the U.S. Food and Drug Administration (FDA).
